Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1958

1.

Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.

PMID:
26017449
2.

Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.

Quante AS, Whittemore AS, Shriver T, Hopper JL, Strauch K, Terry MB.

J Natl Cancer Inst. 2015 May 8;107(7). pii: djv124. doi: 10.1093/jnci/djv124. Print 2015 Jul.

3.

Germline TP53 mutational spectrum in French Canadians with breast cancer.

Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, Tonin PN.

BMC Med Genet. 2015 Apr 12;16:24. doi: 10.1186/s12881-015-0169-y.

4.

[Case of encapsulated solid papillary carcinoma with triple-negative and basal-like phenotype occurred in pregnant woman with review of the literature].

Popovska S, Damianova P, Tomov S, Dineva T, Ivanov I.

Akush Ginekol (Sofiia). 2015;54(2):50-6. Review. Bulgarian.

PMID:
25909142
5.

BRCA1 and BRCA2 mutation type associated with cancer risk.

Burki TK.

Lancet Oncol. 2015 May;16(5):e205. doi: 10.1016/S1470-2045(15)70187-7. Epub 2015 Apr 16. No abstract available.

PMID:
25892146
6.

Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.

Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R, Cacsire Castillo-Tong D.

Cancer Lett. 2015 Jul 1;362(2):218-28. doi: 10.1016/j.canlet.2015.03.040. Epub 2015 Apr 8.

7.

Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.

Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, Friedman E, Korach J.

Fertil Steril. 2015 May;103(5):1305-12. doi: 10.1016/j.fertnstert.2015.02.011. Epub 2015 Mar 16.

PMID:
25792249
8.

Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.

Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, Mourits MJ, van Os TA, Vasen HF, Verhoef S, Rookus MA, Hooning MJ; Hereditary Breast and Ovarian Cancer Research Group Netherlands.

J Natl Cancer Inst. 2015 Mar 18;107(5). pii: djv033. doi: 10.1093/jnci/djv033. Print 2015 May.

PMID:
25788320
9.

A 12-year experience at a tertiary hospital on patients with multiple primary malignant neoplasms.

Papaconstantinou I, Mantzos DS, Asimakoula K, Michalaki V, Kondi-Pafiti A.

J BUON. 2015 Jan-Feb;20(1):332-7.

PMID:
25778335
10.

Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.

Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O'Doherty A, Quinn CM, Green AJ, Bracken A, Geraghty JG.

Eur J Surg Oncol. 2015 May;41(5):641-6. doi: 10.1016/j.ejso.2015.01.021. Epub 2015 Feb 17.

PMID:
25736863
11.

Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.

Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, Rudas M, Singer CF, Helbich TH.

J Clin Oncol. 2015 Apr 1;33(10):1128-35. doi: 10.1200/JCO.2014.56.8626. Epub 2015 Feb 23.

PMID:
25713430
12.

Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.

Francis JC, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J, Assiotis I, Chen L, Kozarewa I, Fenwick K, Swain A, Smalley MJ, Lord CJ, Ashworth A.

J Pathol. 2015 Jun;236(2):186-200. doi: 10.1002/path.4517. Epub 2015 Apr 2.

PMID:
25692405
13.

Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.

Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ.

Gynecol Oncol. 2015 Apr;137(1):86-92. doi: 10.1016/j.ygyno.2015.01.537. Epub 2015 Jan 23.

14.

Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients.

Sokolenko AP, Preobrazhenskaya EV, Aleksakhina SN, Iyevleva AG, Mitiushkina NV, Zaitseva OA, Yatsuk OS, Tiurin VI, Strelkova TN, Togo AV, Imyanitov EN.

Cancer Lett. 2015 Apr 10;359(2):259-61. doi: 10.1016/j.canlet.2015.01.022. Epub 2015 Jan 22.

PMID:
25619955
15.

[Update on genetic predisposition to prostate cancer].

Cussenot O, Cancel-Tassin G.

Bull Cancer. 2015 Jan;102(1):53-6. doi: 10.1016/j.bulcan.2014.12.007. Epub 2014 Dec 29. Review. French.

PMID:
25609482
16.

Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.

Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE.

Am J Surg Pathol. 2015 Mar;39(3):287-93. doi: 10.1097/PAS.0000000000000369.

PMID:
25581732
17.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer.

Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S; EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM; GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC; Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB; HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR; KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmalm M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J; Australian Cancer Study (Ovarian Cancer Investigators); Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1 and BRCA2.

Nat Genet. 2015 Feb;47(2):164-71. doi: 10.1038/ng.3185. Epub 2015 Jan 12.

PMID:
25581431
18.

Precision medicine meets public health: population screening for BRCA1 and BRCA2.

Levy-Lahad E, Lahad A, King MC.

J Natl Cancer Inst. 2014 Dec 30;107(1):420. doi: 10.1093/jnci/dju420. Print 2015 Jan. No abstract available.

PMID:
25550384
19.

Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.

Phi XA, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Tilanus-Linthorst MM, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, de Koning HJ, Van den Heuvel ER, de Bock GH.

J Clin Oncol. 2015 Feb 1;33(4):349-56. doi: 10.1200/JCO.2014.56.6232. Epub 2014 Dec 22.

PMID:
25534390
20.

Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.

van Verschuer VM, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert LB, Verhoog LC, Martens JW, Seynaeve C, van Deurzen CH.

Hum Pathol. 2015 Feb;46(2):182-90. doi: 10.1016/j.humpath.2014.10.020. Epub 2014 Nov 15.

PMID:
25522926
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk